Tinzaparin
Regulatory milestones approvals, filings & regulatory actions · 1 recorded
| Milestone | Jurisdiction | Brand | Indication | Date | Sentence it was read from |
|---|---|---|---|---|---|
| Approved | US (FDA) | INNOHEP | — | 2000-07-14 | fda.gov ↗ |
Trials 45 · a red edge is where a trial was stopped
Also used as a comparator or background therapy in 19 trials
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 01 trial | ||||||
| Phase 0 | NCT03100123 Comparator | Nov 2017 → Oct 2019 | antiphospholipid syndrome, pregnancy disorder with abortive outcome | Ottawa Hospital Research Institute | Terminated | No outcome recorded |
| Phase 22 trials | ||||||
| Phase 2 | NCT03178864 Comparator | Mar 2019 → Oct 2022 | cerebral sinovenous thrombosis | University of British Columbia | Completed | No outcome recorded |
| Phase 2 | NCT00061373 Background | May 2003 → Dec 2009 | ischemic stroke | National Institute of Neurological Disorders and Stroke (NINDS) | Completed | No outcome recorded |
| Phase 2/31 trial | ||||||
| Phase 2/3 | NCT00260988 Comparator | Oct 2003 → Nov 2008 | thrombotic disease | Ottawa Hospital Research Institute | Completed | No outcome recorded |
| Phase 38 trials | ||||||
| Phase 3 | NCT07228663 Comparator | Dec 2025 → Jul 2027 expected | venous thromboembolism | McMaster University | Not yet recruiting | No outcome recorded |
| Phase 3 | NCT06370273 Comparator | Nov 2024 → Aug 2028 expected | thrombotic disease | Queen Mary University of London | Recruiting | No outcome recorded |
| Phase 3 | NCT03240120 Background | Sep 2017 → May 2021 | pulmonary embolism, venous thromboembolism | The University of Hong Kong | Unknown | No outcome recorded |
| Phase 3 | NCT02583191 Comparator | Mar 2016 → Jun 2019 | cancer, venous thromboembolism | AIO-Studien-gGmbH | Terminated | No outcome recorded |
| Phase 3 | NCT02091479 Comparator | Jan 2013 → Jun 2015 | — | University Hospital of Saint-Etienne | Terminated | No outcome recorded |
| Phase 3 | NCT01455831 Comparator | Sep 2011 → Dec 2020 | colon adenocarcinoma | Ottawa Hospital Research Institute | Completed | No outcome recorded |
| Phase 3 | NCT01164046 Comparator | Aug 2010 → Jul 2014 | neoplasm, venous thromboembolism | University Medical Center Groningen | Terminated | No outcome recorded |
| Phase 3 | NCT00238667 Comparator | Nov 2005 → May 2014 | carotid artery dissection, stroke disorder, vertebral artery dissection | St George's, University of London | Completed | No outcome recorded |
| Phase 44 trials | ||||||
| Phase 4 | NCT06020560 Comparator | Mar 2023 → Mar 2025 | venous thromboembolism | Herlev Hospital | Unknown | No outcome recorded |
| Phase 4 | NCT03614741 Comparator | Dec 2018 → Dec 2025 | acute kidney injury | Tampere University Hospital | Unknown | No outcome recorded |
| Phase 4 | NCT01828697 Comparator | Apr 2013 → Oct 2021 | pulmonary embolism, venous thromboembolism | Academic Medical Center - University of Amsterdam | Completed | No outcome recorded |
| Phase 4 | NCT01390051 Comparator | Jul 2011 → Jul 2016 | fetal growth restriction | University of Aarhus | Completed | No outcome recorded |
| Phase not applicable3 trials | ||||||
| — | NCT05058924 Comparator | Aug 2021 → Feb 2024 | venous thromboembolism | Mount Sinai Hospital, Canada | Completed | No outcome recorded |
| — | NCT04730856 Comparator | Feb → Oct 2021 | COVID-19, thrombotic disease | Hospital Universitario Infanta Leonor | Completed | No outcome recorded |
| — | NCT05279391 Comparator | Oct 2020 → Nov 2021 | respiratory failure | Democritus University of Thrace | Unknown | No outcome recorded |
Evidence & citations 7 cited values
Every value below carries the sentence it was read from. 65 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | tinzaparin | “The LMWH regime will be at the discretion of the treating physician, with a suggested regime as follows: tinzaparin 4,500 IU sc daily until 20 weeks gestation, and then 4,500...” NCT03100123 ↗62“Therapeutic low weight molecular heparin (LMWH) tinzaparin, considering its contraindications, recommended dose ranges and monitoring if applicable, as follows: 175 (in...” NCT06381661 ↗ “Enoxaparin, dalteparin, or tinzaparin are acceptable LMWHs to be used for patients in the investigational arm and dose should be based on measured or estimated weight of the patient.” NCT05848713 ↗ “A Pilot Trial of Innohep (Tinzaparin) Low Molecular Weight Heparin for Primary Prophylaxis of Venous Thromboembolism in Brain Tumor Patients” NCT00629447 ↗ “a single daily dose of LMWH (tinzaparin) (Innohep LEO pharmaceutical products.) subcutaneously starting at diagnosis of FGR till delivery” NCT03230162 ↗ “Enoxaparin 40 mg/dalteparin 5000 U/tinzaparin 4500 U subcutaneously daily for women with weight \<100 kg for 6 weeks.” NCT05058924 ↗ “subcutaneous anticoagulation with low molecular weight heparin (tinzaparin) at a prophylactic dose (4500 UI/day)” NCT02580773 ↗ “LMWH (tinzaparin) at body-weight-adjusted therapeutic dose (175 anti-Xa IU/kg subcutaneously once daily)” NCT04196309 ↗ “Patients will receive Tinzaparin sodium 20.000 Anti-Xa IU/ml in prefilled syringes.” NCT05178628 ↗ “received either tinzaparin (175 IU/kg) once daily or warfarin for 6 months” PMID 29618162 ↗ Apr 2018 “Low-molecular weight heparin (dalteparin, enoxaparin, tinzaparin)” NCT03178864 ↗ “including tinzaparin (175 anti-Xa IU/kg subcutaneous once daily)” NCT04372589 ↗ “about 0.5 to 1.5 anti-Xa IU for tinzaparin, 1 injection daily” NCT02091479 ↗ “LMWH options include: Tinzaparin, Enoxaparin, or Dalteparin.” NCT04444700 ↗ “LMWH options include: Tinzaparin, Enoxaparin or Dalteparin.” NCT04362085 ↗ “Therapeutic doses of LMWH (e.g. Tinzaparin 175IU/kg)” NCT05279391 ↗ “Dalteparin, Enoxaparin, Nadroparin, Tinzaparin” NCT06494878 ↗ “Tinzaparin 175 I.E./kg BW once daily” NCT02583191 ↗ “Tinzaparin: 4500 IU subcutaneous OD” NCT07228663 ↗ “tinzaparin 4500-7000IU o.d.” NCT07140211 ↗ “Tinzaparin (Innohep®)” NCT01817257 ↗ “tinzaparin” NCT03230162 ↗ “tinzaparin” NCT01164046 ↗ |
| Known as | Innohep | “A Pilot Trial of Innohep (Tinzaparin) Low Molecular Weight Heparin for Primary Prophylaxis of Venous Thromboembolism in Brain Tumor Patients” NCT00629447 ↗9“A Phase I/II Trial of Tinzaparin (Innohep), a Low Molecular Weight Heparin (LMWH) for Treatment of Advanced Renal Cell Carcinoma” NCT00293501 ↗ “Innohep (tinzaparin) has been shown to be safe and effective for both the initial and long-term treatment of DVT.” NCT00203658 ↗ “tinzaparin (Innohep®) subcutaneously in a fixed dose of 175 IU anti-Xa/kg of body weight once daily for 6 months” NCT00689520 ↗ “Tinzaparin INNOHEP ® 175 IU/kg/24h for 14 days if creatinine clearance Cockcroft ≥ 20mL/min” NCT04344756 ↗ “tinzaparin (Innohep®), a commonly used anti-coagulant” NCT05284552 ↗ “4,500 IU tinzaparin sodium (Innohep®;) or placebo” NCT00225108 ↗ “Long-term treatment with Innohep® only.” NCT01130025 ↗ “Drug: Innohep (tinzaparin)” NCT00260988 ↗ |
| Known as | Tinzaparin (Innohep) | “Tinzaparin (Innohep®)” NCT01817257 ↗ |
| Known as | Tinzaparin sodium | “The purpose of this study is to assess the long-term out-of-hospital treatment of patients with proximal venous thrombosis through the administration of subcutaneous...” NCT00203658 ↗5“The study intends to examine the long-term effects of the replacement of UFH by LMWH (tinzaparin sodium) on cardio-vascular outcomes and on lipoprotein profiles in a large...” NCT00407641 ↗ “4,500 IU tinzaparin sodium (Innohep®;) or placebo” NCT00225108 ↗ “Drug: Tinzaparin sodium” NCT00981903 ↗ “Drug: Tinzaparin Sodium” NCT03090880 ↗ |
| Action | Inhibit | “tinzaparin may stop the growth of kidney cancer by blocking blood flow to the tumor” NCT00293501 ↗ |
| Modality | Other / unclassified | “subcutaneous low-molecular-weight heparin (tinzaparin sodium)” NCT00203580 ↗ |
| Route | Subcutaneous | “administered by subcutaneous (SQ) injection” NCT00061373 ↗ |